Global News

Astrazeneca, University of Cambridge form joint Ph.D., clinical research scholarships

Wednesday, July 1, 2015 10:11 AM

AstraZeneca and the University of Cambridge have formed three new joint schemes to support more than 80 Ph.D. scholarships and eight clinical lectureships over the next five years, spanning translational science, basic and clinical research.

More... »


Celgene, Juno collaborate on cancer and autoimmune diseases

Wednesday, July 1, 2015 09:47 AM

Celgene, headquartered in Summit, N.J., and Seattle-based Juno Therapeutics have formed a global collaboration for the development and commercialization of immunotherapies. The two companies will leverage T cell therapeutic strategies to develop treatments for patients with cancer and autoimmune diseases with an initial focus on Chimeric Antigen Receptor Technology (CAR-T) and T Cell Receptor (TCR) technologies.

More... »


Eolas Therapeutics, AstraZeneca partner

Wednesday, July 1, 2015 09:30 AM

Eolas Therapeutics, a therapeutic development company based in Carlsbad, Calif., has entered into a worldwide license and partnership agreement with AstraZeneca on the Eolas Orexin-1 Receptor Antagonist (EORA) program for smoking cessation and other indications. The EORA program was awarded a Blueprint Neurotherapeutics (BPN) grant from the NIH for the development of the program from the preclinical stage through phase I clinical trials.

More... »

The CenterWatch Monthly, July 2015

Wednesday, July 1, 2015 08:00 AM

Integrated research partnerships build momentum

More... »

Bracket acquires Clintara

Monday, June 29, 2015 10:57 AM

Bracket Global, a provider of clinical research solutions, and Clintara, a privately held clinical service and technology company headquartered in Boston, Mass., have agreed to combine. Bracket will integrate the Clintara platform of surveillance strategies developed for clinical trials within Bracket's proprietary electronic platform for Clinical Outcome Assessments (eCOA). The integration will include Clintara's innovative C-VISA Subject Eligibility Validation program designed to ensure appropriate patients are enrolled in clinical trials.

More... »

Edge Therapeutics’ CEO Brian Leuthner receives EY Entrepreneur of the Year Award

Monday, June 29, 2015 10:43 AM

Brian A. Leuthner, Edge Therapeutics’ CEO, president and co-founder, has received the EY Entrepreneur of the Year 2015 New Jersey Region Award in the Pharmaceutical & Diagnostic Private Companies category. He was selected by an independent judging panel comprising previous winners of the award, CEOs, private capital investors and other regional business leaders.

More... »

Celladon cuts staff, considers liquidation following bad trial results

Monday, June 29, 2015 10:34 AM

Celladon has confirmed plans to suspend further R&D of its MYDICAR (AAV1/SERCA2a) program and its other preclinical programs, including the Stem Cell Factor (mSCF) gene therapy and SERCA2b small molecule programs.

More... »

PharmaEngine receives FDA Priority Review, EMA MMA acceptance for MM-398

Monday, June 29, 2015 10:16 AM

PharmaEngine has announced that its license partner, Merrimack Pharmaceuticals, has received FDA acceptance and Priority Review designation for their NDA and its sublicense partner, Baxalta, a wholly owned subsidiary of Baxter International, has received Market Authorization Application (MAA) from the EMA, of MM-398 (irinotecan liposome injection, also known as nal-IRI) in the treatment of patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy.

More... »

DBV Technologies adds Dr. Hugh Sampson as chief scientific officer

Monday, June 29, 2015 10:10 AM

DBV Technologies, a clinical-stage specialty biopharmaceutical company, has appointed Dr. Hugh Sampson chief scientific officer. In partnership with Dr. Dupont, chairman of the company’s scientific advisory board, Sampson will lead DBV’s research team, pursuing new Viaskin applications for the treatment of food allergies, while also supporting the company’s clinical development teams.

More... »

Report: Venture financing in biotech follows male CEOs and boards

Monday, June 29, 2015 10:07 AM

Gender still plays a role in biotech, with venture financing closely following male CEOs and all male boards, found Liftstream, a London-based company providing executive recruitment services to the biotechnology sector. Liftstream has published a new gender diversity report, Investing in Biotechnology Management, a study of venture financing and hiring trends in European and U.S. biotechnology companies and the gender representation on the boards and at the executive level. The research analyses 110 investment deals in private biotechnology companies as well as 308 biotech executive appointments.

More... »

`

CWWeekly

June 29

FDA and PatientsLikeMe collaborate to test social media adverse event reporting

Boston-area teaching hospitals launch web portal to attract life science companies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

Integrated research partnerships build momentum
Research function provides infrastructure, leverages large pool of health systems' patients and data

'Right to Try' laws challenge clinical trial process
20 states pass, 20 more pending allowing access to study drugs without FDA and IRB approval

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

TransCelerate Biopharma turns three
High-profile consortium has made inroads fixing wasteful practices, but it still has more work ahead

Pharma industry improves its tarnished reputation
Delivering innovation, social responsibility will help rebuild trust

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs